Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling PfizerInvestors Business Daily • 09/14/23
Alnylam Pharmaceuticals shares fall after FDA advisers weigh in on heart-disease drugMarket Watch • 09/14/23
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR AmyloidosisBusiness Wire • 09/13/23
Alnylam Pharmaceuticals' stock to be halted Wednesday as FDA advisory panel reviews treatment for the Cardiomyopathy of ATTR AmyloidosisMarket Watch • 09/13/23
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR AmyloidosisBusiness Wire • 09/13/23
Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some VolatilitySeeking Alpha • 09/09/23
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular RiskBusiness Wire • 09/07/23
First Set of Recommendations Advocating for the Holistic Care of People Living with hATTR Amyloidosis Developed by International Panel of Patient Advocates and Healthcare ProfessionalsBusiness Wire • 09/06/23
Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against ModernaBusiness Wire • 08/25/23
Alnylam (ALNY) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 08/03/23
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/03/23
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period ActivityBusiness Wire • 08/03/23
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth ConferenceBusiness Wire • 08/02/23
Alnylam: Zilebesiran Deal With Roche Reveals A Very Long Development TimelineSeeking Alpha • 07/30/23
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular RiskBusiness Wire • 07/24/23
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/20/23